TrialHeart and vessels2019

Randomized comparison between 2-link cell design biolimus A9-eluting stent and 3-link cell design everolimus-eluting stent in patients with de novo true coronary bifurcation lesions: the BEGIN trial.

Masahiro Yamawaki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.